key: cord-0880368-ze4bvjkt
authors: Perotti, C.; Baldanti, F.; Bruno, R.; Delfante, C.; Seminari, E.; Casari, S.; Percivalle, E.; Glingani, C.; Musella, V.; Belliato, M.; Garuti, M.; Meloni, F.; Frigato, M.; Di Sabatino, A.; Klersy, C.; De Donno, G.; Franchini, M.
title: Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial
date: 2020-05-29
journal: nan
DOI: 10.1101/2020.05.26.20113373
sha: 451ec1ead88288c6241c8dc29ad999e5657df2d4
doc_id: 880368
cord_uid: ze4bvjkt

BACKGROUND Hyperimmune plasma from Covid-19 convalescent is a potential treatment for severe Covid-19. METHODS We conducted a multicenter one arm proof of concept interventional study. Patients with Covid-19 disease with moderate-to-severe Acute Respiratory Distress Syndrome, elevated C-reactive Protein and need for mechanical ventilation and/or CPAP were enrolled. One to three 250-300 ml unit of hyperimmune plasma (neutralizing antibodies titer [≥]1:160) were administered. Primary outcome was 7-days hospital mortality. Secondary outcomes were PaO2/FiO2, laboratory and radiologic changes, as well as weaning from mechanical ventilation and safety. RESULTS The study observed 46 patients from March, 25 to April, 21 2020. Patients were aged 63, 61% male, 30 on CPAP and 7 intubated. PaO2/FiO2 was 128 (SD 47). Symptoms and ARDS duration were 14 (SD 7) and 6 days (SD 3). Three patients (6.5%) died within 7 days. The upper one-sided 90%CI was 13.9%, allowing to reject the null hypothesis of a 15% mortality. PaO2/FiO2 increased by 112 units (95%CI 82 to142) in survivors, the chest radiogram severity decreased in 23% (95%CI 5% to 42%); CRP, Ferritin and LDH decreased by 60, 36 and 20% respectively. Weaning from CPAP was obtained in 26/30 patients and 3/7 were extubated. Five serious adverse events occurred in 4 patients (2 likely, 2 possible treatment related). CONCLUSIONS Hyperimmune plasma in Covid-19 shows promising benefits, to be confirmed in a randomized controlled trial. This proof of concept study could open to future developments including hyperimmune plasma banking, development of standardized pharmaceutical products and monoclonal antibodies.

Since the end of 2019, a new coronavirus strain has been reported in the Chinese province of Wuhan, indicated as 2019-nCoV or SARS-CoV-2 1-3 . The rapid spread of the epidemic in western countries has almost overcome the possibility of response of health systems leading to a high number of hospitalized people and deaths. There has been an inevitable lag between the onset of the pandemic and the availability of an effective therapy, and of today no treatment has been shown convincingly effective [4] [5] [6] [7] . Previous data on the use of convalescent plasma (CP) during the SARS and MERS epidemics suggest the possibility of prompt immunization by administering specific antibodies using plasma from recovered/convalescent subjects 8- 16 .

Also a metanalysis on hyperimmune immunoglobulins in severe acute respiratory infections of viral etiology, published in 2014, concluded for its efficacy and safety, though advocating well designed clinical trials 17 . To date there are very few studies in the literature that demonstrate the feasibility and efficacy of hyperimmune plasma in the SARS-CoV-2 pandemic [18] [19] [20] .

For these reasons, we designed and conducted a proof of concept interventional multicenter study to show the potential efficacy and safety of hyperimmune plasma infusions, obtained from convalescent donors, in COVID-19 patients with respiratory failure, hospitalized at the participating Centers.

This is a proof of concept one-arm multicenter interventional study on the short-term (7 days) efficacy and safety of the infusion of hyperimmune plasma in moderate to severely compromised COVID-19 patients, according to Berlin Score. The evidence obtained will help either to plan an informed large clinical trial or to dismiss the proposed treatment if irrelevant. Primary endpoint of the study is 7-days mortality; secondary endpoints are respiratory function (PaO2/FiO2 ratio), laboratory (CRP, Ferritin, LDH, viral load) and radiologic changes, as well as weaning from mechanical ventilation (CPAP and or naso-tracheal intubation).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05. 26.20113373 doi: medRxiv preprint Two university hospital and one general hospital in Northern Italy. This study has been registered at clinicaltrials.gov as NCT 04321421. It has been approved by the local Ethical Committee on March 17th, 2020 (Number n. 20200027967). Patients were enrolled from March 25, 2020 to April 21, 2020. Follow-up was closed on April 28, 2020.

Eligibility criteria are summarized in the eTable 1. Data were included into a database in REDCap hosted at the Fondazione IRCCS Policlinico San Matteo in Pavia and monitored remotely for missingness. The schedule of assessments is summarized in the eTable 2.

Male adults or female with no previous pregnancy COVID-19 recovered subjects, with 2 consecutive negative naso-pharyngeal swabs performed 7 to 30 days before, were recruited from the hospital records; their suitability was assessed according to the current Italian guidelines and transfusion law 21, 22 . Plasma collection was performed with the latest generation cell separator (Trima Accel -Terumo BCT and Amicus -Fresenius Kabi) devices. A plasma volume of about 660 ml was collected during each procedure and immediately equally divided into two bags using a sterile tubing welder. Plasma pathogen reduction was performed with the INTERCEPT processing system (Cerus Europe BV) or the Mirasol PRT System (Terumo BCT, Lakewood, CO, USA). The collected units were stored at a controlled temperature ranging from -40 to -25°C. 23 (See supplementary material for further details).

Plasma was delivered ready-for-use by the Immuno-Hematology Service to the Covid Units and was administered to the patients over 30 to 60 minutes, under supervision of the treating physician.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2020 

Neutralizing antibodies (NT-Abs) titers against SARS-CoV2 was defined according to the following protocol.

Briefly, 50 µl of sample from each patient, starting from 1:10 in a serial fourfold dilution series, were added in two wells of a flat bottom tissue culture microtiter plate (COSTAR, Corning Incorporated, NY 14831, USA), mixed with an equal volume of 50 TCID50 of a SARS-CoV2 strain isolated from a symptomatic patient, previously titrated and incubated at 33°C in 5% CO2. All dilutions were made in EMEM with addition of 1% penicillin, streptomycin and glutammin and 5 γ/mL of trypsin. After 1 h incubation at 33°C 5%CO2, VERO E6 Neutralizing titer was the maximum dilution with the reduction of 90% of CPE. A positive titer was equal or greater than 1/10. Positive and negative controls were included in all test run.

Considering the hospitalization and mortality data retrieved from the Italian National Institute of Health by march 16 26, 27 we expect a mortality of about 15% (survival 85%; H0) in patients treated according to the standard of care. We also expect the mortality to decrease to 5% (survival 95%; H1) with the proposed hyperimmune plasma infusion. This being a proof of concept study, we use a one-sided type I error of 10%.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05. 26.20113373 doi: medRxiv preprint According to the one stage Fleming design 43 patients will allow a power above 80% to reject H0. If we will observe at least 40 successes, the H0 hypothesis will be rejected and we might proceed with a future definitive trial. Three additional patients are enrolled to allow for possible drop-outs

All continuous variables are summarized using the mean, standard deviation (SD) or the median, interquartile range (IQR). The frequency and percentage is reported for all categorical measures. All enrolled patients who receive the plasma infusion represent the analysis population.

Primary endpoint: The observed mortality rate is computed as the number of deaths over the full analysis population. The one-sided exact binomial confidence interval, at the 90% level (by design) is presented. The clinical and laboratory findings at baseline are described for patients surviving 7 days and listed for patients who died. No formal tests is performed.

Secondary endpoints: To assess changes in PaO2/FiO2, LDH, C reactive protein, Ferritin, and viral load over time we fit repeated measures linear (with Huber-White clustered robust standard errors to account for intra-patient correlation) or bootstrapped median regression models (depending on the distribution); the coefficient contrasting day 7 to day 1 together with its 95%CI are displayed to describe the end of study change.

We enrolled 46 patients from 3 participating centers in this proof-of-concept study; patients were aged 63 years (SD 12) and 28 were male (61%). Mean oxygen saturation was 94% (SD 3) and the PaO2/FiO2 was 128 (SD 47); 14 (33%) had a severe Berlin score; 30 patients (70%) were on CPAP and 7 (16%) were intubated; 19 (41%) had 2 or more comorbidities and 38 (83%) had bilateral multilobe infiltrates at the chest radiogram.

Patients had been having symptoms for 14 days (SD 7) and ARDS for 6 days (SD 3). More than 80% of patients were treated with antibiotics, hydroxychloroquine and anticoagulants (Table 1) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.26.20113373 doi: medRxiv preprint

Twenty-four patients received one unit of plasma, 21 received two units and ne patient received 3 units. The plasma units administered at first infusion had a title of 1:160 or 1:320 in 85% of patients and of 1:320 in 12%; one patient only received 1:80 plasma (Table 1) . At the second infusion titers were 1:80 in two patients, 1:160 in 11, 1:320 in seven and 1:640 in one. The third infusion performed in a single patient had a titer of 1:320.

The plasma infusion was well tolerated in 45/46 patients. It was interrupted in one case.

Three patients out of 46 (6.5%) died within 7 days (at 1, 4 and 6 days); the upper one-sided 90%CI was 13.9%

and 40 out of the first 43 patients enrolled had survived, allowing to reject the null hypothesis of a 15% mortality. The main characteristics of these 3 patients are listed in Table 1 . Among them, two had important comorbidities, such as diabetes, hypertension and cancer, while the third had an extremely low PaO2/FiO2 level of 67 at the time of plasma infusion. Among survivors, the severity of the condition at baseline was confirmed by the low oxygen saturation (mean 94%) and PaO2/FiO2 (mean 131). More than 89% of patients showed bilateral multilobe infiltrates at chest radiogram and all laboratory biomarkers were markedly elevated (Table 1) .

In a concurrent cohort of 23 patients from the Pavia Covid Registry, observed between March 10 and March 24 and satisfying the same entry criteria, the observed mortality was 30% (80%CI 18% -46%).

At 7 days after plasma infusion PaO2/FiO2 increased by 112 units (95%CI 82 to142) in survivors, the chest radiogram severity decreased in 23% of patients (95%CI 5% to 42%); CRP, Ferritin and LDH all decreased by 60, 36 and 20%, respectively (Table 2 and Figure 1 ). Conversely no or little improvement was present in the three deceased patients (Figure 1 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.26.20113373 doi: medRxiv preprint Overall 30 patients were on CPAP and 7 were intubated. Weaning from CPAP was obtained in 26 patients over a median time of 2 days (IQR 0-3) and 3 patients were extubated after a median of 2 days (IQR 1-5). Two out of 16 patients were discharged from ICU within 7 days from infusion, both at day 3.

Two patients were put on ECMO 1 and 6 days, respectively, after the plasma infusion.

Five serious adverse events occurred in 4 patients. In one case the transfusion had to be interrupted. In two cases the relation to treatment was considered as likely and in two as possible (Table 3 ). Three adverse events had no spontaneous resolution and were treated accordingly.

This proof of concept study showed that the infusion of hyperimmune plasma in COVID-19 patients with a severe respiratory failure reduces short-term mortality by 2.5 times, from an expected 15% (that is about 1 out of 6 patients) at the time of study design to 6% (that is about 1 out of 15 patients). Compared with a concurrent series of 23 patients, satisfying the same entry criteria and observed in the period March 10 th -24 th , the decrease in the mortality rate was even more dramatic (5-fold, from 30% to 6%). Only three patients died during the seven days study period. Among them, two had important comorbidities, while the third had extremely low PaO2/FiO2 level at the time of plasma infusion.

Patients had been having symptoms for two weeks at the time of plasma infusion. Most had been on treatment with antibiotics, hydroxychloroquine and anticoagulants. In survivors, PaO2/FiO2 increased by two-fold, paralleled by a decrease in biomarkers: CRP by 60%, ferritin by 36%, and LDH by 20%. The bilateral multilobe infiltrates at chest radiogram disappeared in one-third of the study population. The viral load was reduced to null. Serious adverse events occurred in 4 patients; in two cases, they were likely related to the transfusion. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.26.20113373 doi: medRxiv preprint titer of 1:80 to 1:480, 10 to 20 days after admission. Clinical condition and laboratory findings had improved.

As a result, three patients were discharged, and the other two were still hospitalized after one month. In a second study performed in three hospitals in Wuhan, China 20 the outcomes obtained from ten patients with severe disease treated with convalescent plasma with high neutralizing titers ( ³1:640), 16 days after the onset of symptoms were described. Following clinical and laboratory improvement, three patients had been discharged, and the other seven were ready for discharge. In contrast, in their historical controls, similar for baseline characteristics, only one patient improved, six were stable and three died. A third report of compassionate use of hyperimmune plasma gave encouraging results as well 28 .

On the contrary, in a fourth retrospective study 29 , administration of convalescent plasma in 6 patients led to suboptimal results. No previous determination of neutralizing antibody response had been performed.

Indeed, both the FDA and the European Commission 30,31 strongly recommend defined SARS-CoV-2 neutralizing antibody titers be measured in the donated plasma. While the FDA recommends a minimum neutralizing antibody titer of 1:160, though 1:80 might be acceptable, the EU considers titers of 1:320 or more to be optimal, though lower thresholds could be considered. In our study, of the 68 units of hyperimmune plasma administered, only three (4%) had a titer below 1:160; 58 (84%) had a titer between 1:160 and 1:320 and 7 had a titer of 1:640, largely consistent with the international recommendations. Of note, the promising efficacy of using neutralizing antibodies was described in a recent study that reported on a human monoclonal antibody neutralizing SARS-CoV-2 (and SARS-CoV) in cell culture 32. This study has some limitations, first of all the lack of a randomized control arm; it was however designed as a proof of concept study to verify the potential efficacy and safety of the administration of hyperimmune plasma in severely compromised Covid-19 patients and inform the design of a rigorous controlled randomized trial. However, the mortality was shown to be decreased by the treatment, both when compared to the mortality in Italy at the time of the design of hospitalized patients and to the mortality in our concurrent and similar observational cohort. Second, it was designed at the very beginning of the pandemic in Italy, and the patients were included under the pressure of medical emergency to provide them with an effective treatment at very short term. For this reason, some information was not planned to be collected, such as, but not only, the levels of D-dimer or other markers of inflammation, and long-term outcome.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05. 26.20113373 doi: medRxiv preprint In conclusion, we were able to show a promising benefit of hyperimmune plasma in Covid-19 patients, both through a reduction of mortality, an increase in the respiratory function and a decrease in the inflammatory indices. This is a proof of concept study, thus these findings should not be overinterpreted. Nevertheless, they pave the way to future developments including the rigorous demonstration of hyperimmune plasma efficacy in a randomized clinical trial, the need for hyperimmune plasma banking to anticipate a potential second wave of the pandemic, the development of standardized pharmaceutical products made from the purified antibody fraction (concentrated COVID-19 H-Ig) and, least but not last, the production of monoclonal antibodies on a large scale . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020. We also thank all the donors who after experiencing a difficult time being victims of the Covid-19 disease, are freely giving their convalescent plasma for the benefit of all. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2020 Viral load (U) ° 3.4 (2.1-5.9) 0 (0-3.2) -3.5 (-6.2 to -0.8) °Pavia's cases only . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.26.20113373 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2020. . https://doi.org/10.1101/2020.05.26.20113373 doi: medRxiv preprint Figure 1 A B C D Patients who signed the informed consent. If there is no possibility of obtaining informed consent for the clinical condition (e.g. patients sedated and treated for acute respiratory failure and consequent mechanical ventilation), the patient's consent will be assumed until manifestly stated otherwise.

1 Diagnosis of moderate-severe ARDS for > 10 days 2 Patients with proven hypersensitivity or allergic reaction to blood products or immunoglobulins

Convalescent plasma: new evidence for an old therapeutic tool?

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Passive immunity in prevention and treatment of infectious diseases

Deployment of convalescent plasma for the prevention and treatment of COVID-19

The convalescent sera option for containing COVID-19

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Centro Nazionale Sangue

Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy

Plasma from Donors recovered from new Corona virus 2019 as therapy for critical patients with Covid-19 (COVID-19 PLASMA study). A multicentre study protocol

Diagnostic detection of 2019-nCoV by real-time RT-PCR

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

COVID-19 Italia -Monitoraggio situazione-Dati Regionali

Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients

Center for Biologics Evaluation and Research . Investigational COVID-19 Convalescent Plasma. Guidance for Industry

European Commission Directorate-General For Health And Food Safety. An EU programme of COVID-19 convalescent plasma collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored us

14 (7) 29 2 11Days of ards, mean (SD) 6 (3) 8 1 7